--- title: "Corbus Pharmaceuticals Holdings (CRBP) stock and investor profile" url: "https://aibio.space/companies/corbus-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), United States. The directory classifies it as Pharmaceuticals: Major." --- CRBP Corbus Pharmaceuticals Holdings, Inc. NASDAQ · United States # Corbus Pharmaceuticals Holdings (CRBP) news Financings · 2026-08-07 ## [Corbus Pharmaceuticals sets up sales program for up to $127,500,000](https://aibio.space/news/corbus-pharmaceuticals-sets-up-sales-program-up-127-500-000/) Corbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution. ## Latest Corbus Pharmaceuticals Holdings news We have not published a story on Corbus Pharmaceuticals Holdings yet. When there is news, it will appear here. ## Corbus Pharmaceuticals Holdings at a glance - **Ticker**: CRBP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $117.9 million ### Related companies - [Belite Bio](https://aibio.space/companies/belite-bio/) NASDAQ: BLTE - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) NASDAQ: RLMD - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) NASDAQ: CNSP - [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) OTC: ZVSA - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) NASDAQ: ACRV ### Also on NASDAQ - [Enanta Pharmaceuticals](https://aibio.space/companies/enanta-pharmaceuticals/) ENTA - [AVITA Medical](https://aibio.space/companies/avita-medical/) RCEL - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) ELOX - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) PRLD - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) MPLT ## What Corbus Pharmaceuticals Holdings does Corbus Pharmaceuticals is a clinical stage company focused on oncology and obesity. Its oncology lead, CRB-701, is a next-generation antibody drug conjugate that targets Nectin-4 on cancer cells and releases the cytotoxic payload monomethyl auristatin E. The company licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023 for the U.S., Canada, the European Union, the United Kingdom and Australia. A Phase 1/2 Western study in the U.S. and Europe is in dose expansion, and a combination arm with Keytruda (pembrolizumab) began dosing in June 2025. CRB-701 has FDA fast track designation for relapsed or refractory metastatic cervical cancer and for recurrent or metastatic head and neck squamous cell carcinoma. CSPC is running a Phase 3 trial in cervical cancer in China. The second pipeline asset, CRB-913, is a highly peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. | Product or program | What it is | Stage | |---|---|---| | CRB-701 | Next-generation Nectin-4 targeting antibody drug conjugate with an MMAE payload for solid tumors | Phase 1/2 Western study in dose expansion; Phase 3 in cervical cancer in China by CSPC | | CRB-913 | Highly peripherally restricted cannabinoid type-1 receptor inverse agonist for obesity | | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/crbp-20251231.htm). ## Corbus Pharmaceuticals Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$70.1 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | [$32.2 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | | Net income (loss) | [-$78.5 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | [-$40.2 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | | Cash from operations | [-$64.5 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | [-$41.8 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | | Cash and equivalents | [$28.5 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526338274/) | [$17.2 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | | Short-term investments | [$134.8 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526338274/) | [$131.9 million](https://www.sec.gov/Archives/edgar/data/1595097/000119312526098530/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $23.4 million, plus short-term investments of $94.6 million, $117.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Corbus Pharmaceuticals Holdings What is the ticker symbol of Corbus Pharmaceuticals Holdings? Corbus Pharmaceuticals Holdings, Inc. trades under the ticker CRBP on NASDAQ. Where is Corbus Pharmaceuticals Holdings listed? Corbus Pharmaceuticals Holdings, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:3371; LS:A3D54P; LSE:0SZI; LSX:A3D54P. What is the SEC CIK of Corbus Pharmaceuticals Holdings? The SEC Central Index Key (CIK) for Corbus Pharmaceuticals Holdings, Inc. is 1595097. Its filings are on SEC EDGAR. How many shares does Corbus Pharmaceuticals Holdings have outstanding? 19,341,293 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Corbus Pharmaceuticals Holdings listed under? Our directory records Corbus Pharmaceuticals Holdings, Inc. under United States. What does Corbus Pharmaceuticals Holdings do? Our directory classifies Corbus Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Corbus Pharmaceuticals Holdings? The ISIN recorded for Corbus Pharmaceuticals Holdings, Inc. is US21833P3010. Does aibio.space cover Corbus Pharmaceuticals Holdings? aibio.space lists Corbus Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Corbus Pharmaceuticals Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Corbus Pharmaceuticals Holdings develop? Corbus Pharmaceuticals is a clinical stage company focused on oncology and obesity. Its oncology lead, CRB-701, is a next-generation antibody drug conjugate that targets Nectin-4 on cancer cells and releases the cytotoxic payload monomethyl auristatin E. The company licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023 for the U.S., Canada, the European Union, the United Kingdom and Australia. What is CRB-701 from Corbus Pharmaceuticals Holdings? CRB-701: Next-generation Nectin-4 targeting antibody drug conjugate with an MMAE payload for solid tumors Stage: Phase 1/2 Western study in dose expansion; Phase 3 in cervical cancer in China by CSPC. What is CRB-913 from Corbus Pharmaceuticals Holdings? CRB-913: Highly peripherally restricted cannabinoid type-1 receptor inverse agonist for obesity Stage: not stated. Is Corbus Pharmaceuticals Holdings profitable? Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $78.5 million for the fiscal year ended Dec 31, 2025, and used $64.5 million of cash in operations, per its annual report to the SEC. How much does Corbus Pharmaceuticals Holdings spend on research and development? $70.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Corbus Pharmaceuticals Holdings have? $117.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Corbus Pharmaceuticals Holdings Members talk about Corbus Pharmaceuticals Holdings (CRBP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Corbus Pharmaceuticals Holdings, newest first. Each line links the filing it comes from. 1. 2026-08-07 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1595097/000119312526340378/crbp_424b5_2026_08_07.htm) 2. 2026-07-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-ex99_1.htm) 3. 2026-05-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/crbp-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRBP on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRBP/). ## SEC filings and registration - **SEC name**: Corbus Pharmaceuticals Holdings, Inc. - **CIK**: 1595097 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CRBP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062 - **Phone**: 617-963-0103 - **Shares outstanding**: 19,341,293 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: SAV Acquisition Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526422437/crbp-20261015.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm) filed 2026-09-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1595097/000119312526340378/crbp_424b5_2026_08_07.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1595097/000119312526338274/crbp-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-20260702.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm) filed 2026-05-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/crbp-20260519.htm) filed 2026-05-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001595097), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Corbus Pharmaceuticals Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRBP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Corbus Pharmaceuticals Holdings, Inc. - **Ticker**: CRBP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US21833P3010 - **Other listed symbols**: GETTEX:3371; LS:A3D54P; LSE:0SZI; LSX:A3D54P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRBP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/corbus-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Corbus Pharmaceuticals Holdings (CRBP) stock and investor profile", 2026-10-31, https://aibio.space/companies/corbus-pharmaceuticals/